Media coverage about Medpace Holdings (NASDAQ:MEDP) has been trending somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Medpace Holdings earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.1919146241967 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

MEDP has been the subject of several analyst reports. Jefferies Group LLC reissued a “hold” rating and issued a $25.50 target price (down previously from $35.50) on shares of Medpace Holdings in a research note on Wednesday, May 3rd. Wells Fargo & Co downgraded shares of Medpace Holdings from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 3rd. ValuEngine downgraded shares of Medpace Holdings from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. Zacks Investment Research downgraded shares of Medpace Holdings from a “hold” rating to a “strong sell” rating in a research note on Friday, May 5th. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $36.00 target price (up previously from $35.00) on shares of Medpace Holdings in a research note on Tuesday, June 6th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $34.00.

Shares of Medpace Holdings (NASDAQ:MEDP) traded up 0.22% on Wednesday, reaching $32.22. 92,424 shares of the company traded hands. Medpace Holdings has a 52-week low of $21.76 and a 52-week high of $38.94. The firm has a 50-day moving average of $29.83 and a 200-day moving average of $29.21. The company has a market capitalization of $1.27 billion and a PE ratio of 56.73.

Medpace Holdings (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, July 31st. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.30 by $0.08. Medpace Holdings had a return on equity of 9.32% and a net margin of 5.37%. The business had revenue of $94.60 million during the quarter, compared to analysts’ expectations of $92.71 million. During the same period in the previous year, the firm earned $0.45 earnings per share. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities research analysts forecast that Medpace Holdings will post $1.43 earnings per share for the current fiscal year.

In other Medpace Holdings news, major shareholder Medpace Limited Partnership sold 2,000,000 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $30.27, for a total value of $60,540,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 25.80% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/medpace-holdings-medp-earning-somewhat-favorable-news-coverage-analysis-shows/1532442.html.

Medpace Holdings Company Profile

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Receive News & Ratings for Medpace Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.